1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Baker Bros. Advisors Lp Buys ACADIA Pharmaceuticals Inc, Amarin Corp PLC, Clementia Pharmaceuticals Inc, Sells Sage Therapeutics Inc, Invitae Corp, Endocyte Inc

New York, NY, based Investment company Baker Bros. Advisors Lp buys ACADIA Pharmaceuticals Inc, Amarin Corp PLC, Clementia Pharmaceuticals Inc, Krystal Biotech Inc, Ra Pharmaceuticals Inc, Audentes Therapeutics Inc, Marker Therapeutics Inc, Zymeworks Inc, Aeglea BioTherapeutics Inc, Sierra Oncology Inc, sells Sage Therapeutics Inc, Invitae Corp, Endocyte Inc, Neurocrine Biosciences Inc, Galapagos NV, Erytech Pharma SA, Momenta Pharmaceuticals Inc, Xencor Inc, Arrowhead Pharmaceuticals Inc, Sangamo Therapeutics Inc, Autolus Therapeutics PLC, Halozyme Therapeutics Inc, bluebird bio Inc, Ovid Therapeutics Inc, Intellia Therapeutics Inc, Foamix Pharmaceuticals, Galmed Pharmaceuticals, Alkermes PLC, ChemoCentryx Inc, Achillion Pharmaceuticals Inc, Y-mAbs Therapeutics Inc during the 3-months ended 2018Q4, according to the most recent filings of the investment company, Baker Bros. Advisors Lp. As of 2018Q4, Baker Bros. Advisors Lp owns 89 stocks with a total value of $12.1 billion. These are the details of the buys and sells.

For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to https://www.gurufocus.com/guru/baker+bros.+advisors+lp/current-portfolio/portfolio

These are the top 5 holdings of BAKER BROS. ADVISORS LP
  1. Seattle Genetics Inc (SGEN) - 51,046,060 shares, 23.97% of the total portfolio.
  2. Incyte Corp (INCY) - 34,251,607 shares, 18.05% of the total portfolio.
  3. BeiGene Ltd (BGNE) - 11,959,824 shares, 13.90% of the total portfolio.
  4. Alexion Pharmaceuticals Inc (ALXN) - 8,555,894 shares, 6.90% of the total portfolio.
  5. Genomic Health Inc (GHDX) - 11,744,010 shares, 6.27% of the total portfolio. Shares reduced by 14.84%
New Purchase: Marker Therapeutics Inc (GX1N)

Baker Bros. Advisors Lp initiated holding in Marker Therapeutics Inc. The purchase prices were between $3.68 and $7.94, with an estimated average price of $6.29. The stock is now traded at around $4.93. The impact to a portfolio due to this purchase was 0.07%. The holding were 1,500,000 shares as of .

New Purchase: Sierra Oncology Inc (SRRA)

Baker Bros. Advisors Lp initiated holding in Sierra Oncology Inc. The purchase prices were between $1.1 and $1.94, with an estimated average price of $1.59. The stock is now traded at around $1.92. The impact to a portfolio due to this purchase was 0.02%. The holding were 2,000,000 shares as of .

Added: ACADIA Pharmaceuticals Inc (ACAD)

Baker Bros. Advisors Lp added to a holding in ACADIA Pharmaceuticals Inc by 39.65%. The purchase prices were between $14.32 and $22.92, with an estimated average price of $19.3. The stock is now traded at around $26.92. The impact to a portfolio due to this purchase was 1.51%. The holding were 39,713,842 shares as of .

Added: Amarin Corp PLC (AMRN)

Baker Bros. Advisors Lp added to a holding in Amarin Corp PLC by 25.02%. The purchase prices were between $12.41 and $22.98, with an estimated average price of $18.17. The stock is now traded at around $18.86. The impact to a portfolio due to this purchase was 0.96%. The holding were 42,592,824 shares as of .

Added: Clementia Pharmaceuticals Inc (CMTA)

Baker Bros. Advisors Lp added to a holding in Clementia Pharmaceuticals Inc by 92.61%. The purchase prices were between $9.21 and $15.69, with an estimated average price of $12.52. The stock is now traded at around $25.80. The impact to a portfolio due to this purchase was 0.17%. The holding were 3,724,445 shares as of .

Added: Krystal Biotech Inc (KRYS)

Baker Bros. Advisors Lp added to a holding in Krystal Biotech Inc by 584.26%. The purchase prices were between $15.03 and $25.38, with an estimated average price of $21.04. The stock is now traded at around $22.19. The impact to a portfolio due to this purchase was 0.12%. The holding were 784,674 shares as of .

Added: Audentes Therapeutics Inc (BOLD)

Baker Bros. Advisors Lp added to a holding in Audentes Therapeutics Inc by 131.54%. The purchase prices were between $18.43 and $36.7, with an estimated average price of $25.59. The stock is now traded at around $38.50. The impact to a portfolio due to this purchase was 0.09%. The holding were 910,463 shares as of .

Added: Ra Pharmaceuticals Inc (RARX)

Baker Bros. Advisors Lp added to a holding in Ra Pharmaceuticals Inc by 362.55%. The purchase prices were between $11.58 and $18.31, with an estimated average price of $15.65. The stock is now traded at around $27.09. The impact to a portfolio due to this purchase was 0.09%. The holding were 823,113 shares as of .

Sold Out: Sage Therapeutics Inc (SAGE)

Baker Bros. Advisors Lp sold out a holding in Sage Therapeutics Inc. The sale prices were between $81.94 and $139.71, with an estimated average price of $113.76.

Sold Out: Endocyte Inc (ECYT)

Baker Bros. Advisors Lp sold out a holding in Endocyte Inc. The sale prices were between $14.93 and $24, with an estimated average price of $22.16.

Sold Out: Erytech Pharma SA (ERYP)

Baker Bros. Advisors Lp sold out a holding in Erytech Pharma SA. The sale prices were between $5.54 and $9.23, with an estimated average price of $7.45.

Sold Out: Momenta Pharmaceuticals Inc (MNTA)

Baker Bros. Advisors Lp sold out a holding in Momenta Pharmaceuticals Inc. The sale prices were between $10.32 and $22.99, with an estimated average price of $13.68.

Sold Out: Arrowhead Pharmaceuticals Inc (ARWR)

Baker Bros. Advisors Lp sold out a holding in Arrowhead Pharmaceuticals Inc. The sale prices were between $10.74 and $19.7, with an estimated average price of $13.53.

Sold Out: Ovid Therapeutics Inc (OVID)

Baker Bros. Advisors Lp sold out a holding in Ovid Therapeutics Inc. The sale prices were between $2.42 and $6.6, with an estimated average price of $4.52.

Reduced: Invitae Corp (NVTA)

Baker Bros. Advisors Lp reduced to a holding in Invitae Corp by 53.54%. The sale prices were between $9.26 and $14.86, with an estimated average price of $12.85. The stock is now traded at around $24.68. The impact to a portfolio due to this sale was -0.5%. Baker Bros. Advisors Lp still held 3,902,421 shares as of .

Reduced: Neurocrine Biosciences Inc (NBIX)

Baker Bros. Advisors Lp reduced to a holding in Neurocrine Biosciences Inc by 22.68%. The sale prices were between $68.32 and $119.1, with an estimated average price of $94.71. The stock is now traded at around $87.62. The impact to a portfolio due to this sale was -0.17%. Baker Bros. Advisors Lp still held 730,355 shares as of .

Reduced: Galapagos NV (GLPG)

Baker Bros. Advisors Lp reduced to a holding in Galapagos NV by 89.43%. The sale prices were between $87.81 and $109.06, with an estimated average price of $101.19. The stock is now traded at around $101.06. The impact to a portfolio due to this sale was -0.16%. Baker Bros. Advisors Lp still held 25,072 shares as of .

Reduced: Xencor Inc (XNCR)

Baker Bros. Advisors Lp reduced to a holding in Xencor Inc by 26.94%. The sale prices were between $32.39 and $42.05, with an estimated average price of $36.73. The stock is now traded at around $30.27. The impact to a portfolio due to this sale was -0.04%. Baker Bros. Advisors Lp still held 440,186 shares as of .

Reduced: Sangamo Therapeutics Inc (SGMO)

Baker Bros. Advisors Lp reduced to a holding in Sangamo Therapeutics Inc by 22.13%. The sale prices were between $9.51 and $15.33, with an estimated average price of $12.29. The stock is now traded at around $9.74. The impact to a portfolio due to this sale was -0.03%. Baker Bros. Advisors Lp still held 999,823 shares as of .

Reduced: Halozyme Therapeutics Inc (HALO)

Baker Bros. Advisors Lp reduced to a holding in Halozyme Therapeutics Inc by 33.34%. The sale prices were between $13.33 and $18.66, with an estimated average price of $15.87. The stock is now traded at around $16.74. The impact to a portfolio due to this sale was -0.02%. Baker Bros. Advisors Lp still held 299,969 shares as of .



Here is the complete portfolio of BAKER BROS. ADVISORS LP. Also check out:

1. BAKER BROS. ADVISORS LP's Undervalued Stocks
2. BAKER BROS. ADVISORS LP's Top Growth Companies, and
3. BAKER BROS. ADVISORS LP's High Yield stocks
4. Stocks that BAKER BROS. ADVISORS LP keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK